Kindred Biosciences (KIN) Misses Q3 EPS by 2c

Kindred Biosciences (NASDAQ: KIN) reported Q3 EPS of ($0.39), $0.02 worse than the analyst estimate of ($0.37). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Medtronic jumps on earnings beat and raised guidance
• New Zealand Energy Corp. swings to profit in Q2 2026
• UBS Reiterates Buy Rating on Cheniere Energy (LNG)